Integrated Diagnostics Holdings (IDGXF) AI Stock Analysis

Integrated Diagnostics Holdings

(Other OTC:IDGXF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Broad-Based Revenue and Volume GrowthStrong growth across revenue, testing volumes, and patients indicates expanding demand and deeper utilization of IDH’s diagnostic platform. This broad-based performance supports operating leverage, strengthens provider and patient reach, and provides a durable foundation for continued earnings growth over the next several quarters.

Negative Factors

Saudi Business Remains Below Break-EvenSaudi expansion is generating rapid revenue growth but has not yet reached break-even, meaning the business currently consumes resources while management builds utilization and scale. Continued losses could dilute Group margins and cash generation until the branch network matures and operating leverage improves.

Integrated Diagnostics Holdings (IDGXF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $261.60M
Dividend Yield: 4.29%
Average Volume (3M): 2,968
Price to Earnings (P/E): 9.7
Beta (1Y): 0.48
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 7,137
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Integrated Diagnostics Holdings Business Overview & Revenue Model

Company Description

Integrated Diagnostics Holdings plc (IDHC.L) functions as a leading consumer healthcare enterprise, offering a wide array of medical diagnostic services directly to its clientele. The company's comprehensive service catalog features around 2,000 dist...

Integrated Diagnostics Holdings Earnings Call Summary

Earnings Call Date:Sep 10, 2026(Q2-2026)|% Change Since:12.67%|Next Earnings Date:Nov 20, 2018

Earnings Call SentimentPositive

The call was strongly positive overall. Highlights significantly outweighed the lowlights, with 37% revenue growth, record testing volume, expanding margins, 47% net profit growth, improved Nigeria performance, and rapid Saudi expansion. The main challenges were geopolitical uncertainty, constrained Sudan operations, Saudi Arabia remaining below break-even, higher working capital balances, lower net cash, and the decision not to pay an interim dividend.

Positive Updates

Strong Broad-Based First-Half Growth

IDH reported broad-based operational and financial growth in H1 2026, with revenue increasing 37% year-on-year to EGP 4.9 billion. Test volumes rose 20% to 23.6 million, average revenue per test increased 14% to EGP 206, and patients served increased 14% to 4.9 million.

Negative Updates

Geopolitical and Macroeconomic Uncertainty

Management said evolving macroeconomic conditions and regional developments may introduce volatility across parts of the Group's footprint. Egypt's inflation remained sensitive to currency movements and energy-related pressures, the Egyptian Pound experienced renewed pressure earlier in 2026, and management is monitoring potential effects on economic activity, patient volumes, and consumer sentiment.

Company Guidance

For 2026, management is forecasting revenue of EGP 11 billion, gross profit of 46%, EBITDA margin of 37%, and net profit margin of 20%; margins are expected “to have the same margins until the full year of 2026,” with Q3 and Q4 expected “to be resilient” and “a good second half of 2026 with high margins.” Egypt is expected to add “around 50 more branches in H2,” while Saudi Arabia’s plan is to open nine branches this year, with five opened and four to go, and to reach 50 branches in three years; Nigeria is not expected to open more branches, with the focus on increasing revenue, patient footprint, tests, and profitability from existing branches. Management said a 4% price increase implemented during the second quarter “will continue for the rest of the year,” but also said, “We are not planning to do any price increase for the rest of the year,” and confirmed that “for this quarter, there will be no dividend distribution.”

Integrated Diagnostics Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IDGXF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:BVXP	89Outperform	GBP 104.50M	13.79	67.81%	7.50%	-1.10%	0.32%
GB:EKF	64Neutral	GBP 102.71M	41.38	3.58%	―	2.26%	-57.04%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:GDR	49Neutral	GBP 15.65M	-0.89	-1044.57%	―	65.60%	74.84%
GB:ABDX	46Neutral	GBP 22.75M	-16.36	-34.31%	―	30.42%	43.16%
GB:CNSL	45Neutral	GBP 3.69M	-0.63	-69.62%	―	-16.27%	-471.21%

* Healthcare Sector Average

Performance Comparison

IDGXF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IDGXF	Integrated Diagnostics Holdings	0.59	0.08	16.01%
GB:BVXP	Bioventix plc	2000.00	-17.66	-0.88%
GB:EKF	EKF Diagnostics Holdings	24.00	-2.20	-8.40%
GB:GDR	Genedrive plc	0.97	0.01	1.25%
GB:CNSL	Omega Diagnostics	1.55	-1.10	-41.51%
GB:ABDX	Abingdon Health PLC	9.00	2.75	44.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Integrated Diagnostics Holdings AI Stock Analysis